SCHEMBL2832950

SCHEMBL2832950

CC#CCOC(=O)c1ccc(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CES2 O00748 2/20 0.49
CES1 P23141 2/20 0.49
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 2/20 0.45
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13337474 0.84 MAOB (0.44) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL2834792 0.82 NPC1 (0.61) RAB9AALDH1A1CES2CES1TDP1
SCHEMBL2838283 0.81 NPC1 (0.54) ALDH1A1CES2CES1L3MBTL1GAA
SCHEMBL2831854 0.81 MMP1 (0.43) RAB9AALDH1A1CES2CES1GAA
SCHEMBL2169187 0.80 ALDH1A1 (0.47) RAB9AALDH1A1CES2CES1TDP1
SCHEMBL367075 0.80 TSHR (0.57) RAB9AALDH1A1CES2CES1TDP1
SCHEMBL2834381 0.79 KMT2A (0.49) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL2831433 0.77 ADRB2 (0.50) RAB9AALDH1A1CES2CES1TDP1
SCHEMBL13291853 0.77 RAB9A (0.55) RAB9AALDH1A1CES2CES1TDP1
SCHEMBL30954392 0.75 CES2 (0.68) RAB9AALDH1A1CES2CES1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 RAB9A 643/4885ALDH1A1 2511/4885CES2 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.